Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $51.3 million.

  • Silence Therapeutics' Cash from Investing Activities rose 234.48% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.0 million, marking a year-over-year increase of 55.34%. This contributed to the annual value of -$22.0 million for FY2024, which is 213.85% down from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Cash from Investing Activities is $51.3 million, which was up 3,383.55% from -$1.6 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year Cash from Investing Activities high stood at $66.1 million for Q4 2024, and its period low was -$49.9 million during Q1 2024.
  • For the 3-year period, Silence Therapeutics' Cash from Investing Activities averaged around $386,133, with its median value being -$43,000 (2024).
  • In the last 5 years, Silence Therapeutics' Cash from Investing Activities surged by 52,887.24% in 2023 and then plummeted by 32,177.59% in 2024.
  • Over the past 5 years, Silence Therapeutics' Cash from Investing Activities (MRQ) stood at $6.0 million in 2021, then crashed by 420.80% to -$19.3 million in 2022, then soared by 102.46% to $474,120 in 2023, then skyrocketed by 13,846.89% to $66.1 million in 2024, then fell by 22.44% to $51.3 million in 2025.
  • Its Cash from Investing Activities was $51.3 million in Q3 2025, compared to -$1.6 million in Q2 2025 and -$44.4 million in Q1 2025.